Unknown

Dataset Information

0

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.


ABSTRACT: The goal of this study was to characterize the molecular mechanisms underlying cetuximab-mediated upregulation of HLA class I antigen-processing machinery components in head and neck cancer (HNC) cells and to determine the clinical significance of these changes in cetuximab-treated HNC patients. Flow cytometry, signaling studies, and chromatin immunoprecipitation (ChIP) assays were performed using HNC cells treated with cetuximab alone or with Fc? receptor (Fc?R)-bearing lymphocytes to establish the mechanism of EGFR-dependent regulation of HLA APM expression. A prospective phase II clinical trial of neoadjuvant cetuximab was used to correlate HLA class I expression with clinical response in HNC patients. EGFR blockade triggered STAT1 activation and HLA upregulation, in a src homology-containing protein (SHP)-2-dependent fashion, more prominently in HLA-B/C than in HLA-A alleles. EGFR signaling blockade also enhanced IFN? receptor 1 (IFNAR) expression, augmenting induction of HLA class I and TAP1/2 expression by IFN?, which was abrogated in STAT1(-/-) cells. Cetuximab enhanced HNC cell recognition by EGFR853-861-specific CTLs, and notably enhanced surface presentation of a non-EGFR peptide (MAGE-3271-279). HLA class I upregulation was significantly associated with clinical response in cetuximab-treated HNC patients. EGFR induces HLA downregulation through SHP-2/STAT1 suppression. Reversal of HLA class I downregulation was more prominent in clinical responders to cetuximab therapy, supporting an important role for adaptive immunity in cetuximab antitumor activity. Abrogating EGFR-induced immune escape mechanisms and restoring STAT1 signaling to reverse HLA downregulation using cetuximab should be combined with strategies to enhance adaptive cellular immunity.

SUBMITTER: Srivastava RM 

PROVIDER: S-EPMC4526378 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

Srivastava Raghvendra M RM   Trivedi Sumita S   Concha-Benavente Fernando F   Hyun-Bae Jie J   Wang Lin L   Seethala Raja R RR   Branstetter Barton F BF   Ferrone Soldano S   Ferris Robert L RL  

Cancer immunology research 20150513 8


The goal of this study was to characterize the molecular mechanisms underlying cetuximab-mediated upregulation of HLA class I antigen-processing machinery components in head and neck cancer (HNC) cells and to determine the clinical significance of these changes in cetuximab-treated HNC patients. Flow cytometry, signaling studies, and chromatin immunoprecipitation (ChIP) assays were performed using HNC cells treated with cetuximab alone or with Fcγ receptor (FcγR)-bearing lymphocytes to establish  ...[more]

Similar Datasets

| S-EPMC5635422 | biostudies-literature
| S-EPMC5345631 | biostudies-literature
| S-EPMC6348820 | biostudies-literature
| S-EPMC8516652 | biostudies-literature
| S-EPMC6791452 | biostudies-literature
| S-EPMC4701504 | biostudies-literature
| S-EPMC11319473 | biostudies-literature
| S-EPMC10214068 | biostudies-literature
| S-EPMC6350839 | biostudies-literature
| S-EPMC8385668 | biostudies-literature